On a preliminary basis, Luminex (NASDAQ:LMNX) expects Q4 and full-year revenues of $90.4M (+11%) and $334.6M (+6%), respectively.
2020 guidance: Revenues: $352M – 362M.
#JPM20
Sunday, January 12, 2020
Baxter announces preliminary 2019 results
On a preliminary basis, Baxter International (NYSE:BAX) expects Q4 and full-year sales of ~$3.0B and ~$11.4B, respectively.
Operating margin should be above guidance of 15.2 – 15.9% of sales.
2020 guidance: Sales growth: 4 – 5%; operating margin: 17 – 18%. More detailed guidance will be released when it reports Q4 and 2019 results which will be later than usual due to its ongoing internal investigation into certain intra-company transactions aimed at generating non-operating foreign exchange gains or avoiding losses (first disclosed in October 2019).
#JPM20
Hologic sees FQ1 revenue of ~$851M
On a preliminary basis, Hologic (NASDAQ:HOLX) expects FQ1 revenues of ~$850.5M (+2%). Breast health and Diagnostics should account for $331.1M (+2%) and $311.5M (+5%), respectively.
Board OKs new $500M share buyback program.
It will provide updated 2020 guidance when it reports final FQ1 results.
#JPM20
Neurocrine Bio expects $238M in Q4 Ingrezza sales
On a preliminary basis, Neurocrine Biosciences (NASDAQ:NBIX) expects Ingrezza (valbenazine) sales in Q4 and 2019 to be ~$238M (+83%) and ~$753M (+84%), respectively.
Quick assets at year-end: $970M.
Q1 2020 Ingrezza sales to be negatively impacted by payer-related seasonal dynamics, gross-to-net discount increases from payers, Medicare Part D rebates and potential reduction in channel inventory.
Management does not intend to guide on 2020 Ingrezza sales.
#JPM20
Cutera announces preliminary 2019 revenue
On a preliminary basis, Cutera (NASDAQ:CUTR) expects Q4 and full-year revenue of $51M – 52M (+12 – 14%) and $180.9M – 181.9M (+11 – 12%), respectively.
GW Pharma releases preliminary 2019 results
Exact Sciences sees almost $300M in Q4 revenue
On a preliminary basis, Exact Sciences (NASDAQ:EXAS) expects Q4 and full-year revenue of $294M – 296M and $874.5M – 876.5M, respectively. Screening revenue should be $229M – 230M (+61%) and $809.5M – 810.5M (+78%), respectively.
Cologuard test volume: 477K (+63%) and 1.68M (+80%), respectively.
Oncotype DX test volume: 41K (+14%) and 156K (+14%), respectively.
Management will provide 2020 guidance during its Q4 earnings call next month.
#JPM20
Subscribe to:
Posts (Atom)